GH Secretagogues Compared: Ipamorelin, CJC-1295, Sermorelin, Tesamorelin

The one fact that reorganizes everything: only tesamorelin is approved

It is tempting to treat ipamorelin, CJC-1295, sermorelin, and tesamorelin as four flavors of the same thing. They are not. Of the four, exactly one — tesamorelin — has cleared the bar of FDA approval, and only for a narrow indication: "the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy" (the EGRIFTA SV label, initial U.S. approval 2010). Everything else in this comparison — ipamorelin, CJC-1295, and even sermorelin in its current marketing — sits in research-only or compounding-gray territory, without a modern randomized-trial dossier behind a general-wellness claim.

This matters because the marketing language is engineered to blur that line. "GH peptide," "secretagogue blend," and "natural growth hormone optimization" are phrases that travel easily across all four molecules, and they imply an equivalence of evidence that does not exist. A useful mental model: tesamorelin is a prescription drug with a phase III record; the other three are interesting molecules with mostly mechanistic, preclinical, or small/old human pharmacology data. When you read any claim about these peptides, the first question is always which molecule, and the second is whether the evidence is human or animal.

Two mechanisms, not one: GHRH analogues vs. ghrelin agonists

All four peptides are "secretagogues" — they coax the pituitary into releasing its own growth hormone rather than supplying GH from outside. But they pull two different levers.

Three of them — sermorelin, CJC-1295, and tesamorelin — are GHRH analogues. They mimic growth-hormone-releasing hormone, binding the GHRH receptor on pituitary somatotrophs to stimulate GH synthesis and release. Sermorelin is essentially the first 29 amino acids of human GHRH (GRF 1-29), the shortest fragment that retains full activity. Tesamorelin is a stabilized 44-amino-acid GHRH analogue carrying an N-terminal trans-3-hexenoic acid group that increases resistance to enzymatic (DPP-4) degradation. CJC-1295 is a modified GRF(1-29) backbone; in its DAC (drug affinity complex) form it adds a maleimide group that covalently binds circulating albumin, dramatically extending its half-life.

Ipamorelin is the odd one out. It is not a GHRH analogue at all — it is a synthetic pentapeptide ghrelin-receptor (GHS-R1a) agonist, a "GH secretagogue" in the original pharmacological sense. It triggers GH release through a separate receptor and signaling pathway (phospholipase C, IP3/DAG). This is why combination products pair a GHRH analogue with ipamorelin: the two mechanisms are complementary, and in classic GH physiology a GHRH signal plus a ghrelin signal produces more GH release than either alone. The pairing is mechanistically coherent; that does not make any specific marketed combination a proven human therapy.

The IGF-1 axis: where the downstream effects actually happen

None of these peptides act primarily by themselves at the tissue level. They raise GH, and most of GH's anabolic and metabolic signaling is relayed through insulin-like growth factor 1 (IGF-1), produced largely by the liver in response to GH. The tesamorelin label states this plainly: tesamorelin stimulates pituitary GH release, and "subsequently increases IGF-1 and IGFBP-3 levels," with some effects mediated directly by GH and others through IGF-1 generated in the liver and peripheral tissues.

This axis is the reason the secretagogue approach is theoretically attractive and also why it carries the same fundamental caveats as growth hormone itself. Because the signal still has to pass through the pituitary, a person with a disrupted hypothalamic-pituitary axis cannot respond normally — which is precisely why "disruption of the hypothalamic-pituitary axis" is a contraindication on the tesamorelin label. And because GH and IGF-1 are growth factors, the same axis that drives lean-mass and fat-distribution effects is the axis that raises oncologic caution. IGF-1 is therefore both the mechanism of benefit and the safety signal to watch; it is not an inert readout.

Tesamorelin: the only one with a phase III human record

Tesamorelin's approval rests on real, named, randomized human trials — the kind of evidence the other three peptides lack. The pivotal data came from a multicenter, randomized, placebo-controlled trial published by Falutz and colleagues in the New England Journal of Medicine in 2007 ("Metabolic effects of a growth hormone-releasing factor in patients with HIV," N Engl J Med 357:2359-2370), which showed that tesamorelin selectively reduced visceral adipose tissue in HIV patients with central fat accumulation, with a corresponding rise in IGF-1. A subsequent randomized trial with a safety extension (Falutz et al., JAIDS, 2010) reported roughly an 18% reduction in visceral fat in patients who continued treatment, alongside improvements in body-image distress and some lipid parameters.

Research then extended into liver fat. Stanley and colleagues, in a randomized clinical trial published in JAMA in 2014 ("Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation"), found tesamorelin reduced liver fat, generating ongoing interest in NAFLD in the HIV setting (summarized in The Lancet HIV, 2019). Two honest caveats: this evidence base is specifically in HIV-associated lipodystrophy, not the general population, and the label explicitly notes that long-term cardiovascular safety has not been established and that the drug is not indicated for general weight loss. The visceral-fat benefit is real and trial-backed — within the population it was studied in.

Ipamorelin, CJC-1295, and sermorelin: what the evidence really is

Strip away the marketing and the evidence picture for the other three is far thinner — and of a different kind.

Ipamorelin's foundational papers are pharmacology and animal work. It was introduced by Raun and colleagues in the European Journal of Endocrinology in 1998 ("Ipamorelin, the first selective growth hormone secretagogue"), characterized largely in animal models and in vitro, and prized for releasing GH without meaningfully raising cortisol or prolactin — a selectivity advantage over earlier secretagogues. Later work explored it in unrelated contexts such as a rodent model of postoperative ileus (J Pharmacol Exp Ther, 2009). What you will not find is a body of modern phase III human efficacy trials for muscle, anti-aging, or fat loss.

CJC-1295 is best understood as a half-life engineering project: a GRF(1-29) analogue (DAC version) designed to bind albumin and sustain GH and IGF-1 elevation for days after a single dose. The pharmacokinetic concept is documented, but durable human outcome data are sparse, and the molecule is not an approved drug.

Sermorelin is the historical exception with the most clinical lineage — it was previously marketed in the U.S. (as Geref) and used as a diagnostic agent for assessing GH secretion and in pediatric GH-deficiency contexts before being withdrawn from that market for commercial, not safety, reasons. Today it circulates mainly through compounding pharmacies for off-label "GH optimization," a use that is not the same as a current FDA-approved indication with a supporting efficacy dossier. For all three, the responsible framing is: mechanistically plausible, partly studied in humans for narrow or historical purposes, but not proven for the wellness uses they are most often sold for.

Reading the safety signal: why malignancy keeps coming up

The shared mechanism produces a shared safety theme. Because every one of these peptides ultimately raises GH and IGF-1, the cautions attached to the only approved member are the most concrete safety data available for the whole class. The tesamorelin label lists active malignancy as an absolute contraindication, requires preexisting malignancies to be inactive with treatment completed before starting, and directs discontinuation on any evidence of recurrence — explicitly because GH is a known growth factor. Other label contraindications include disruption of the hypothalamic-pituitary axis, pregnancy, and hypersensitivity.

The label also flags effects you would expect from raising GH: glucose intolerance and the potential to worsen or unmask diabetes, fluid retention, and injection-site reactions. None of this proves that ipamorelin, CJC-1295, or sermorelin carry identical risks at identical magnitudes — they have different potencies, half-lives, and far less long-term human safety surveillance. But it is the wrong inference to assume the unapproved peptides are safer simply because they are smaller or "more natural." Less data is not the same as less risk; it is the absence of the long-term, controlled safety follow-up that tesamorelin actually accumulated.

How to compare them honestly

A clean way to hold these four molecules in your head: sort first by mechanism, then by evidence. Mechanistically, three are GHRH analogues (sermorelin, CJC-1295, tesamorelin) and one is a ghrelin-receptor agonist (ipamorelin), and all four converge on the GH-to-IGF-1 axis. By evidence, there is a steep cliff: tesamorelin has phase III randomized trials and an FDA approval in a defined population; sermorelin has historical clinical and diagnostic use but no current approved wellness indication; ipamorelin and CJC-1295 rest mainly on pharmacology, preclinical, and limited human data.

The single most useful habit when evaluating any claim about these peptides is to refuse the category shortcut. "GH peptides boost growth hormone" is true and nearly meaningless; what matters is whether the specific molecule has been shown to produce a specific outcome in humans, in a population like the one making the claim, in a controlled trial. For tesamorelin, in HIV lipodystrophy, the answer is yes. For the rest, in the general population, the most accurate answer today is: not established. That is not a knock on the molecules — it is the current state of the evidence, and an honest comparison has to say so.